SCHEMBL19829260

SCHEMBL19829260

CC(C)[C@H](N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 20/20 1.00
▸ BLK P51451 2/20 0.75
▸ EGFR P00533 3/20 0.74
▸ LCK P06239 2/20 0.74
▸ ITK Q08881 2/20 0.74
▸ TEC P42680 2/20 0.74
▸ TXK P42681 2/20 0.74
▸ BMX P51813 2/20 0.74
▸ RIPK2 O43353 1/20 0.74
▸ NR1I2 O75469 1/20 0.74
▸ SLC22A3 O75751 1/20 0.74
▸ LATS1 O95835 1/20 0.74
▸ NUDT14 O95848 1/20 0.74
▸ ABL1 P00519 1/20 0.74
▸ ERBB2 P04626 1/20 0.74
▸ FYN P06241 1/20 0.74
▸ PGR P06401 1/20 0.74
▸ CSF1R P07333 1/20 0.74
▸ YES1 P07947 1/20 0.74
▸ LYN P07948 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19649266 1.00 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL17951540 0.95 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL19649380 0.95 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL30615739 0.94 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL17951543 0.94 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL19638204 0.94 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL25735923 0.93 BTK (0.89) BTKBLKEGFRLCKITK
SCHEMBL19638269 0.93 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL30615719 0.93 BTK (1.00) BTKBLKEGFRLCKITK
SCHEMBL19638268 0.93 BTK (1.00) BTKBLKEGFRLCKITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266535-B2 Inhibitor of FLT3 kinase and use thereof HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2019-04-23 — — US disclosed
US-20180030054-A1 NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2018-02-01 — — US disclosed
US-20180030054-A1 NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2018-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030054-A1 NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF FLT3, FLT1, FGFR1 BTK 32/4885BLK 146/4885EGFR 160/4885
US-10266535-B2 Inhibitor of FLT3 kinase and use thereof FLT3, FLT1, FGFR1 BTK 35/4885BLK 134/4885EGFR 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback